Compare Novartis AG (NVS) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance

Novartis AGTrade

YieldMax Magnificent 7 Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.68. The key difference: Novartis AG pays a 3.17% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Novartis AG is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.

	NVS	YMAG
Market Cap	$290.25B	—
Sector	Health	Income / Options Overlay
52-Week High	$168.62	$15.98
52-Week Low	$113.50	$11.00
Enterprise Value	$330.27B	—
Dividend Yield	3.17%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG trades at $11.63, up 0.17% with a neutral technical signal. The ETF provides weekly dividend distributions, recently ranging from $0.07 to $0.40 per share. Key financial ratios are unavailable, but the fund's strategy focuses on option income from Magnificent Seven stocks. Recent news highlights consistent distribution announcements and tactical performance discussions.

Outlook hinges on option income strategy effectiveness in volatile markets. Opportunities include high yield potential, but risks involve NAV decay and expense ratio drag. Investor sentiment is mixed, with some analysts citing underperformance versus benchmarks amid low implied volatility reducing yield potential.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 23 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

YMAG

YieldMax ETFs declare weekly distributions for multiple option income ETFs starting July 23, 2026.Na · 10 hours agoNeutral View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.